Insider trade

Officer sold ~$1.16M of CORT shares in the open market

Traded Aug 17, 2026 · Filed Aug 19, 2026

Why it stands out

Corcept Therapeutics's Chief Business Officer sold $1.16M of Corcept Therapeutics shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

OfficerIndirect holding$1M+

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$1,162,572

Shares × reported transaction price

Timing vs results

19 days after results of Jul 29, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+0.7%	−0.4%	+1.1%
30 days	−7.3%	−1.0%	−6.4%

Past results only. Not a forecast.

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.00 to $116.54 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
These shares are held by Gary Charles Robb TTE Robb Revocable Trust of which the Reporting Person is trustee.

3w ago

Derivative exercise or conversion — not an open-market buy.

3w ago

Derivative exercise or conversion — not an open-market buy.

Scheduled in advance3w ago